Novartis

Novartis India refutes media reports of negotiations with Alkem Labs

27 Sep 2024

Novartis India, has refuted media reports stating that its parent company is in talks with Mumbai-based Alkem Labs for sale of the Indian arm.

Siemens Healthineers submits binding offer for Novartis’s molecular imaging business

27 Aug 2024

Siemens Healthiness AG is reported to have submitted a binding offer for acquiring the molecular imaging business of Swiss Drugmaker Novartis.

Novartis to acquire US-based Mariana Oncology in $1.75 bn deal

03 May 2024

Swiss drug maker Novartis has agreed to acquire US-based Mariana Oncology in a deal worth $1.75 billion, as the company seeks advance the development of precision treatment for cancer.

Novartis announces strategic review of its India business

19 Feb 2024

Swiss pharma multinational Novartis AG has started a strategic review of its Indian arm, possibly with the intent of selling it off.

Novartis to cut up to 8,000 jobs globally as it restructures business

01 Jul 2022

Novartis to acquire US cancer drugs maker Endocyte for $2.1 billion

19 Oct 2018

Novartis to pay up to $1 bn for experimental skin drug

20 Jul 2018

Novartis plans to spin off eye care division Alcon; buy back, $5 bn shares

29 Jun 2018

Aurobindo in race to acquire generic dermatology business from Novartis

07 May 2018

GSK to sell Horlicks and India business for $4 bn to acquire Novartis

28 Mar 2018

Page no. 1 of 4

1
2
3
4
Next
Last

Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.

Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!

Start your free subscription today!

Latest articles on Novartis from Informachine

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

11 Dec 2024

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

11 Dec 2024

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

11 Dec 2024

Biologist to Head-hunter | Novartis

29 Nov 2024

Applying toNovartis? Our associate shares their career journey with Novartis and experience of relocating to Ireland, sharing their tips and advice.

Addressing unmet needs for inherited neuromuscular diseases | Novartis

29 Nov 2024

Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.

My Journey to Novartis: Finding my Purpose and Passion | Novartis

29 Nov 2024

When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely dif

Medical congresses and events

29 Oct 2024

Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.